Fatal rhabdomyolysis following the co-prescription of fusidic acid and pravastatin

Med Mal Infect. 2015 Oct;45(10):417-9. doi: 10.1016/j.medmal.2015.09.006. Epub 2015 Oct 21.

Authors

K Bachoumas¹, M Fiancette², J-B Lascarrou², J-C Lacherade², F Leclair², J Reignier²

Affiliations

¹ Service de réanimation médicale polyvalente, CHD de La-Roche-sur-Yon, Les Oudairies, 85000 La-Roche-sur-Yon, France. Electronic address: [email protected].
² Service de réanimation médicale polyvalente, CHD de La-Roche-sur-Yon, Les Oudairies, 85000 La-Roche-sur-Yon, France.

PMID: 26472060
DOI: 10.1016/j.medmal.2015.09.006

No abstract available

Keywords: Acide fusidique; Fusidic acid; Pravastatin; Pravastatine; Rhabdomyolyse; Rhabdomyolysis.

Publication types

Case Reports

MeSH terms

Acute Kidney Injury / chemically induced*
Aged
Anti-Bacterial Agents / adverse effects*
Anti-Bacterial Agents / pharmacokinetics
Anti-Bacterial Agents / therapeutic use
Biotransformation
Comorbidity
Cytochrome P-450 Enzyme System / metabolism
Drug Interactions
Fatal Outcome
Fusidic Acid / adverse effects*
Fusidic Acid / pharmacokinetics
Fusidic Acid / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypercholesterolemia / drug therapy
Male
Osteitis / drug therapy
Pravastatin / adverse effects*
Pravastatin / pharmacokinetics
Pravastatin / therapeutic use
Rhabdomyolysis / chemically induced*
Staphylococcal Infections / drug therapy
Tibia

Substances

Anti-Bacterial Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Fusidic Acid
Cytochrome P-450 Enzyme System
Pravastatin